| 来那度胺治疗弥漫大B细胞淋巴瘤的进展 |
| |
| 引用本文： | 杨融辉,李诗文,沈 静,廖爱军. 来那度胺治疗弥漫大B细胞淋巴瘤的进展[J]. 现代肿瘤医学, 2018, 0(1): 120-123. DOI: 10.3969/j.issn.1672-4992.2018.01.032 |
| |
| 作者姓名： | 杨融辉 李诗文 沈 静 廖爱军 |
| |
| 作者单位： | 中国医科大学附属盛京医院第二血液内科，辽宁 沈阳 110000 |
| |
| 基金项目： | National Natural Science Foundation of China(No.81272629）；国家自然科学基金(编号:81272629) |
| |
| 摘 要： | 来那度胺作为免疫调节药物已被广泛应用于多发性骨髓瘤的治疗，其不仅能直接诱导肿瘤细胞凋亡，还通过炎症因子、NK细胞、调节T细胞等发挥重要的免疫调节作用。此外，多项基础及临床研究均证实来那度胺在弥漫大B细胞淋巴瘤（diffuse large B cell lymphoma，DLBCL）治疗中也可起到非常重要的作用，无论对初诊还是复发/难治DLBCL患者，来那度胺单药或联合R-CHOP等方案均取得较好的治疗效果。本文旨在综述来那度胺在治疗DLBCL的进展。
|
| 关 键 词： | 来那度胺 弥漫大B细胞淋巴瘤 复发/难治 免疫调节 化疗 |
Advances of lenalidomide therapy for diffuse large B cell lymphoma |
| |
| Yang Ronghui,Li Shiwen,Shen Jing,Liao Aijun. Advances of lenalidomide therapy for diffuse large B cell lymphoma[J]. Journal of Modern Oncology, 2018, 0(1): 120-123. DOI: 10.3969/j.issn.1672-4992.2018.01.032 |
| |
| Authors: | Yang Ronghui Li Shiwen Shen Jing Liao Aijun |
| |
| Affiliation: | Department of Hematology，Shengjing Hospital of China Medical University，Liaoning Shenyang 110000，China. |
| |
| Abstract: | Lenalidomide as an immunomodulator has been widely used in multiple myeloma.It not only can directly induce the apoptosis of tumor cells，but also plays an important role in immune regulation via inflammatory cytokines，NK cells and regulatory cells.In addition，a number of basic and clinical researches confirmed that lenalidomide can also play a very important role in diffuse large B cell lymphoma (DLBCL) therapy，no matter for the newly diagnosed or relapsed/refractory DLBCL patients.Lenalidomide monotherapy or combination of R-CHOP or other regimens have achieved good results.This article is to review the advances of lenalidomide in the treatment of DLBCL. |
| |
| Keywords: | lenalidomide diffuse large B cell lymphoma relapsed/refractory immune regulation chemotherapy |
|
| 点击此处可从《现代肿瘤医学》浏览原始摘要信息 |
|
点击此处可从《现代肿瘤医学》下载免费的PDF全文 |
